Adamis Pharmaceuticals (ADMP) Enters The Oversold Zone: Time To Buy?
Many stocks are now falling off their record highs and it has been no different for Adamis Pharmaceuticals Corporation (NASDAQ: ADMP).
However, at the same time, it should be noted that when a stock falls from its highs it can also present an opportunity for new investors. Hence, it might be a good idea to perhaps take a closer look at the recent developments. While there has been no recent news, it is necessary to keep in mind that the company made a major announcement back on February 17.
Adamis announced at the time that the United States Patent and Trademark Office allowed its patent application for its naloxone injection product. It is a significant development for the company since it could potentially strengthen its portfolio of patents. The company also believes that its intellectual property has been further strengthened due to this development. Investors could consider keeping the stock in their watch lists at this point.